1. 製薬企業の研究開発費と利益率の推移（日本）出所：SPEEDA （株式会社ユーザベース），有価証券報告書出典：日本製薬工業協会 DATABOOK2021
2. 製薬企業の研究開発費と利益率の推移（米国）出所：SPEEDA（株式会社ユーザベース），アニュアルレポート出典：日本製薬工業協会 DATABOOK2021
3. 開発段階別化合物数と承認取得数（日本）-その 1- 出所：日本製薬工業協会調べ（研究開発委員会メンバーのうち内資系企業の集計）出典：日本製薬工業協会 DATABOOK2021
4. 開発段階別化合物数と承認取得数（日本）-その 2- 出所：日本製薬工業協会調べ（研究開発委員会メンバーのうち内資系企業の集計）出典：日本製薬工業協会 DATABOOK2021
5. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019; 20(2): 273–86.
6. Puffenbarger RA. Molecular biology of the enzymes that degrade endocannabinoids. Curr Drug Targets CNS Neurol Disord. 2005; 4(6): 625–31.
7. Labar G, Michaux C. Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers. 2007; 4(8): 1882-902.
8. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001; 22(11): 565-72.
9. Vaughan CW, Christie MJ. Retrograde signaling by endocannabinoids. Handb Exp Pharmacol. 2005; 168: 367-83.
10. McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther. 2007; 14(5): 475-83.
11. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999; 83(4): 637-49.
12. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers. 2007; 4(8): 1744-69.
13. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim- Selley LJ, Lichtman AH, Wiley JL, Cravatt BF. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009; 106(48): 20270-5.
14. Wise LE, Shelton CC, Cravatt BF, Martin BR, Lichtman AH. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol. 2007; 557(1): 44-8.
15. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. Int J Fertil. 1999; 44(2): 56-66.
16. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Kerrebroeck VP, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167-78.
17. Andersson K-E. The overactive bladder: Pharmacologic basis of drug treatment. Urology. 1997; 50(Suppl 6A): 74-84.
18. Milsom I, Stewart W, Thüroff J. The prevalence of overactive bladder. Am J Manag Care. 2000; 6(11 Suppl): S565-73.
19. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006; 17(6): 636-41.
20. Dmitrieva N, Berkley KJ. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci. 2002; 22(16): 7147-53.
21. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001; 22(11): 565-72.
22. Krieger JN, Nyberg L Jr, Nickel JC. Letter to the editor. NIH Consensus Definition and Classification of Prostatitis. JAMA. 1999; 282(3): 236-7.
23. Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F, de C Williams AC. EAU Guidelines on chronic pelvic pain. Eur Urol. 2010; 57(1): 35- 48.
24. Schaeffer AJ. Chronic prostatitis and the chronic pelvic pain syndrome. N Eng J Med. 2006; 355(16): 1690-8.
25. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001; 165(3): 842-5.
26. McNaughton Collins M, Pontari MA, O’Leary MP, Calhoun EA, Santanna J, Landis JR, Kusek JW, Litwin MS, the Chronic Prostatitis Collaborative Research Network. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med. 2001; 16(10): 656-62.
27. Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T, Wein A. Bladder pain syndrome International consultation on incontinence. Neurourol Urodynam. 2010; 29(1): 191-8.
28. Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun EA. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 2005 Jan; 173(1): 98-102.
29. Kusek JW, Nyberg LM. The epidemiology of interstitial cystitis: is it time to expand our definition? Urology. 2001; 57(6 Suppl 1): 95-9.
30. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J Urol. 1999; 161(2): 549-52.
31. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Brown SO, Gao SY, Calhoun EA. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Brown SO, Gao SY, Calhoun EA. Prevalence of interstitial cystitis symptoms in a managed care population. J Urol. 2005; 174(2): 576-80.
32. Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LM Jr, McKinlay JB. BACH Survey Investigators. Prevalence of painful bladder symptoms and effect on quality of life in black, hispanic and white men and women. J Urol. 2007; 177(4): 1390-4.
33. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011; 186(2): 540-4.
34. Hanno PM. Interstitial cystitis and related diseases. In Walsh PC, Retik AB, Vaughan ED, et al (Eds.). Campbell’s Urology, 8th Ed. Philadelphia: WB Saunders; 2002; 631- 70.
35. Declaration of Helsinki (June 1964). World Medical Association. https://www.wma.net/wp-content/uploads/2018/07/DoH Jun1964.pdf
36. ICH Harmonised tripartite guideline, guideline for good clinical practice (10 June 1996) https://www.pmda.go.jp/files/000156725.pdf
37. ICH Guidelines https://www.ich.org/page/ich-guidelines
38. U.S. Department of Health and Human Services, Guidance for Industry, Food-Effect Bioavailability and Fed Bioequivalence Studies (December 2002)． https://www.gmp-compliance.org/files/guidemgr/5194fnl.pdf
39. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974; 47(3): 211-8.
40. McNair D, Lorr M, Doppleman L. Manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971.
41. Chait LD, Fischman MW, Schuster CR. ‘Hangover’ effects the morning after marijuana smoking. Drug Alcohol Depend. 1985; 15(3): 229–238.
42. Ozalp A, Barroso B. Simultaneous quantitative analysis of N-acylethanolamides in clinical samples. Anal Biochem. 2009; 395(1): 68-76.
43. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004; 56(12): 1825-57.
44. Jhee SS, Zarotsky V. Safety and Tolerability of Serial Cerebrospinal Fluid (CSF) Collections During Pharmacokinetic/Pharmacodynamic Studies: 5 Years Experience. Clin Res Regul Aff. 2003; 20(3): 357-63.
45. U.S. Department of Health and Human Services, Guidance for Industry, Assessment of Abuse Potential of Drugs (January 2017)． https://www.fda.gov/media/116739/download
46. van Steveninck AL, Wallnöfer AE, Schoemaker RC, Pieters MS, Danhof M, van Gerven JM, Cohen AF. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol. 1997; 44(3): 267-75.
47. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers. Relationship to steady state plasma concentrations. Anesthesiology. 1998; 88(1): 82-8.
48. Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984; 18(Suppl 1): 69S-72S.
49. Sternberg S. High-speed scanning in human memory. Science. 1966; 153(3736): 652-4.
50. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935; 18(3): 643-62.
51. Hommer DW, Matsuo V, Wolkowitz O, Chrousos G, Greenblatt DJ, Weingartner H, Paul SM. Benzodiazepine sensitivity in normalhuman subjects. Arch Gen Psychiatry. 1986; 43: 542–51.
52. Pawsey S, Wood M, Browne H, Donaldson K, Christie M, Warrington S. Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled Phase I study in healthy volunteers. Drugs R D. 2016; 16(2): 181-91.
53. Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M, Zannikos P, van der Ark P, Palmer JA, Rassnick S, Celen S, Bormans G, van Laere K. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multipleascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 2018; 11(4): 397-404.
54. Li GL, Winter H, Arends R, Jay GW, Le V, Young T, Huggins JP. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 2012; 73(5): 706-16.
55. Chaikin P. The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials. J Clin Pharmacol. 2017; 57(6): 690-703.
56. 製薬企業の研究開発費の段階別構成比（米国）出所：PhRMA：2001-2012 年 Industry Profile，2013 年以降 PhRMA Annual Membership Survey 出典：日本製薬工業協会 DATABOOK2021
57. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012; 17(9-10): 419-24.
58. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamrén B, Johnson A, March RE, Matcham J, Mettetal J, Nicholls DJ, Platz S, Rees S, Snowden MA, Pangalos MN. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discovery. 2018; 17(3): 167-81.
59. Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM, Majek A, Vjaters E, Urban M, Ramonas H, Shoskes DA, Nickel JC. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology. 2017; 103: 191-7.
60. Houbiers JGA, van Till JWO, Kaper M, Yavuz Y, Martina RV, Cerneus D, Melis J, Stroosma O, Nickel JC, Hanno PM, Nordling J. An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions. World J Urol. 2021; 39(6): 2065-71.
61. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008; 53(1): 60-7.
62. Hanno PM, Erickson D, Moldwin R, Faraday MM; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015; 193(5): 1545-53.
63. Hakimi Z, Houbiers J, Pedersini R, Vietri J. The Burden of Bladder Pain in Five European Countries: A Cross-sectional Study. Urology. 2017; 99: 84-91.
論文の公開元へ
